Igm Biosciences Stock Investor Sentiment

IGMS Stock  USD 10.04  0.39  3.74%   
Slightly above 67% of IGM Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding IGM Biosciences suggests that many traders are alarmed. IGM Biosciences' investing sentiment can be driven by a variety of factors including economic data, IGM Biosciences' earnings reports, geopolitical events, and overall market trends.
  

IGM Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards IGM Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at thelincolnianonline.com         
Brokerages Set IGM Biosciences, Inc. PT at 16.13
news
few days ago at news.google.com         
IGM Biosciences Shares Gap Down - Heres What Happened - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
IGM Biosciences, Inc. Given Consensus Rating of Hold by Brokerages - MarketBeat
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Misbah Tahir of 66667 shares of IGM Biosciences subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
IGM Biosciences Price Target Raised to 27.00
news
over two weeks ago at gurufocus.com         
FMR LLC Increases Stake in IGM Biosciences Inc
Gurufocus Stories at Macroaxis
over two weeks ago at simplywall.st         
IGM Biosciences Insiders Who Sold Avert US165m Market Cap Dip
Simply Wall St News at Macroaxis
over two weeks ago at bizjournals.com         
Biotech firm pivots to autoimmune diseases amid Q3 results
bizjournals News
over two weeks ago at zacks.com         
IGM Biosciences, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over two weeks ago at finance.yahoo.com         
IGM Biosciences Is In A Good Position To Deliver On Growth Plans
Yahoo News
over two weeks ago at finance.yahoo.com         
Acquisition by Steven Weber of 6700 shares of IGM Biosciences subject to Rule 16b-3
Yahoo News
over three weeks ago at finance.yahoo.com         
IGM Biosciences to Present at Three Upcoming Investor Conferences
Yahoo News
over three weeks ago at www.macroaxis.com         
Disposition of 55000 shares by Misbah Tahir of IGM Biosciences at 40.27 subject to Rule 16b-3
Macroaxis News
over three weeks ago at zacks.com         
Kymera Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates
zacks News
over three weeks ago at zacks.com         
Amgen Beats Q3 Earnings Estimates
zacks News
Far too much social signal, news, headlines, and media speculation about IGM Biosciences that are available to investors today. That information is available publicly through IGM media outlets and privately through word of mouth or via IGM internal channels. However, regardless of the origin, that massive amount of IGM data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of IGM Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of IGM Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to IGM Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive IGM Biosciences alpha.

IGM Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 925 shares by Lisa Decker of IGM Biosciences at 11.5388 subject to Rule 16b-3
09/13/2024
2
IGM Biosciences, Inc. CEO Fred Schwarzer Sells 3,946 Shares
09/18/2024
3
While shareholders of IGM Biosciences are in the black over 1 year, those who bought a week ago arent so fortunate
09/27/2024
4
IGM Biosciences downgraded to Hold, stock falls
10/01/2024
5
Acquisition by Harler Mary Beth of 185000 shares of IGM Biosciences subject to Rule 16b-3
10/02/2024
6
Acquisition by Baker Bros. Advisors Lp of 1994 shares of IGM Biosciences subject to Rule 16b-3
10/04/2024
7
Acquisition by Bruce Keyt of 24019 shares of IGM Biosciences subject to Rule 16b-3
10/25/2024
8
Disposition of 55000 shares by Misbah Tahir of IGM Biosciences at 40.27 subject to Rule 16b-3
11/01/2024
9
IGM Biosciences Is In A Good Position To Deliver On Growth Plans
11/07/2024
10
IGM Biosciences Insiders Who Sold Avert US165m Market Cap Dip
11/12/2024
11
Acquisition by Misbah Tahir of 66667 shares of IGM Biosciences subject to Rule 16b-3
11/18/2024
12
Brokerages Set IGM Biosciences, Inc. PT at 16.13
11/27/2024

Additional Tools for IGM Stock Analysis

When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.